Selukos 25 mg/ ml Noruega - noruec - Statens legemiddelverk

selukos 25 mg/ ml

mylan healthcare norge as - selendisulfid - sjampo - 25 mg/ ml

Femke 30 mg Noruega - noruec - Statens legemiddelverk

femke 30 mg

mylan ab - ulipristalacetat - tablett, filmdrasjert - 30 mg

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unió Europea - noruec - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Copemyl 40 mg/ ml Noruega - noruec - Statens legemiddelverk

copemyl 40 mg/ ml

mylan ab - glatirameracetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 40 mg/ ml

Isoptin 120 mg Noruega - noruec - Statens legemiddelverk

isoptin 120 mg

mylan healthcare norge as - verapamilhydroklorid - tablett, filmdrasjert - 120 mg

Klacid 25 mg/ ml Noruega - noruec - Statens legemiddelverk

klacid 25 mg/ ml

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 25 mg/ ml

Klacid 50 mg/ ml Noruega - noruec - Statens legemiddelverk

klacid 50 mg/ ml

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 50 mg/ ml

Serkep 25 mikrog / 250 mikrog Noruega - noruec - Statens legemiddelverk

serkep 25 mikrog / 250 mikrog

mylan ab - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 250 mikrog

Serkep 25 mikrog / 125 mikrog Noruega - noruec - Statens legemiddelverk

serkep 25 mikrog / 125 mikrog

mylan ab - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 125 mikrog

Dovprela (previously Pretomanid FGK) Unió Europea - noruec - EMA (European Medicines Agency)

dovprela (previously pretomanid fgk)

mylan ire healthcare limited - pretomanid - tuberkulose, multidrug-resistent - antimykobakterielle - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.